NAT MED: Antioxidant Key Protein Spromotes Relapse of Dormant Tumor Cells?

Dormant tumor cells survive and relapse after treatment are the leading causes of death in cancer patientsPrevious studies have shown that the metabolic properties of these cells may differ from those of fast-growing tumor cellsrecently, researchers found that lowering Her2 in breast cancer cells promotes changes in cell metabolism, which eventually leads to an increase in oxidative stress and the compensation of the antioxidant transcription factor NRF2NRF2 is activated in dormant and recurrent tumors in animal models and breast cancer patients with poor prognosisThe constituent activation of NRF2 accelerates relapse, while inhibition of NRF2 reduces recurrencein recurrent tumors, NRF2 signalconduction induced transcription hyperbole reprogramming to reconstruct redox balance and boost deoxynucleotide synthesisNRF2-driven metabolic states make recurrent tumor cells sensitive to the inhibition of glutamine, preventing dormant tumor cells from being reactivated in vitro, suggesting that NRF2-high dormant and recurrent tumors may be targeted for treatmenttherefore, these data provide evidence that NRF2-driven metabolic reprogramming promotes the recurrence of dormant breast cancer